Physician profile
Zeshaan Maan
NPI 1174907083
$16,817.13
in general payments reported to CMS, 2019-2025
16 companies · $11K in 2025
The $11K reported for 2025 was more than what 96% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $2,574 · 2023: $1,608 · 2024: $972 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,700 · Food and Beverage: $3,402 · Travel and Lodging: $2,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,700.00 |
| Food and Beverage | $3,402.38 |
| Travel and Lodging | $2,756.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $11,666.70 | 2021-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Abbvie INC. | $1,357.69 | 2023-2024 | |
| Evolution Surgical, INC | $1,200.00 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $1,076.40 | 2022-2023 | |
| Axogen | $615.76 | 2021-2022 | |
| Checkpoint Surgical, INC | $157.32 | 2022 | |
| Davol INC. | $145.68 | 2021 | |
| Depuy Synthes Sales INC. | $137.13 | 2025 | Matrixmandible |
| Revance Therapeutics, INC. | $104.20 | 2024-2025 | Daxi |
| Mentor Worldwide LLC | $95.93 | 2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Motiva USA, LLC | $67.95 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $50.62 | 2025 | |
| Allergan, INC. | $47.76 | 2022 | |
| Biotissue Holdings INC. | $41.04 | 2024 | |
| Rti Surgical, INC | $31.75 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $21.20 | 2024 | Stravix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeshaan Maan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.